(Q52903765)

9 May 2018

title

Adalimumab for the treatment of psoriatic arthritis. (English)

1 reference

9 May 2018

0 references

1

1 reference

9 May 2018

author name string

Martin Rudwaleit

series ordinal

2

1 reference

9 May 2018

publication date

1 November 2009

1 reference

9 May 2018

Expert Review of Clinical Immunology

published in

1 reference

9 May 2018

volume

5

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

671-681

1 reference

9 May 2018

Epidemiology of psoriatic arthritis in the population of the United States.

cites work

1 reference

Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study

21 January 2018

1 reference

Treatment recommendations for psoriatic arthritis.

21 January 2018

1 reference

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

Adalimumab for the treatment of ankylosing spondylitis

21 January 2018

1 reference

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

21 January 2018

1 reference

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

21 January 2018

1 reference

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

21 January 2018

1 reference

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

21 January 2018

1 reference

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

21 January 2018

1 reference

Adalimumab for the treatment of severe psoriasis and psoriatic arthritis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.09.50

1 reference

9 May 2018

1 reference

9 May 2018